Beckman Coulter Life Sciences, in collaboration with Illumina, has introduced a new method for accelerating oncology research. The Illumina TruSight™ Oncology 500 DNA/RNA assay, utilized on the Biomek NGeniuS System, offers a streamlined and automated solution for conducting comprehensive genomic profiling of tumor samples.
This innovative application supports inputs of both DNA and RNA, allowing for the identification of crucial cancer biomarkers such as single nucleotide variants, insertions, deletions, gene amplifications, fusions, and splice events. With the ability to complete library preparation in under three days, researchers can obtain faster results with automated precision from sample preparation through to sequencing.
The Biomek NGeniuS System can process anywhere from four to 24 libraries in a single batch, accommodating a range of sample qualities including high-quality and low-quality FFPE samples. Not only does this system offer efficiency, but it is also designed to minimize plastic usage and reduce consumable costs, making advanced research more accessible and environmentally sustainable.
This new application is part of the broader Biomek NGeniuS System Applications Library, which includes other options such as the Illumina DNA Prep, DNA PCR-Free Prep, and RNA Prep with Enrichment applications. These applications are all part of an open chemistry, cloud-based system, providing researchers with a comprehensive suite of tools for their genomic studies.
The Biomek NGeniuS System is specifically designed for low to medium throughput NGS library preparation, offering an intuitive automation solution that minimizes user errors, manual transfers, and hands-on time typically associated with NGS library construction. By streamlining these processes, researchers can focus more on data analysis and interpretation rather than manual labor.
The collaboration between Beckman Coulter Life Sciences and Illumina continues to yield automation applications tailored to various research fields, including cancer research, infectious disease research, and targeted sequencing. This latest addition, the Illumina TruSight Oncology 500 DNA/RNA sample preparation method, underscores the commitment of both companies to advancing scientific research through innovative technologies.
If you’re interested in staying up-to-date with the latest developments in science, consider becoming a SelectScience member for free to receive science news directly to your inbox.